- Home
- OCS
as 11-15-2024 4:00pm EST
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
| Founded: | 2003 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 706.3M | IPO Year: | N/A |
| Target Price: | $29.20 | AVG Volume (30 days): | 73.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.60 - $18.00 | Next Earning Date: | 11-07-2024 |
| Revenue: | $1,027,571 | Revenue Growth: | -4.82% |
| Revenue Growth (this year): | 4.38% | Revenue Growth (next year): | 905.09% |
Latest Oculis Holding AG Ordinary shares News
OCS Breaking Stock News: Dive into OCS Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Oculis to Present at the Stifel 2024 Healthcare Conference
GlobeNewswire
4 days ago
Oculis to Present at the Stifel 2024 Healthcare Conference
Simply Wall St.
9 days ago
Oculis Holding Third Quarter 2024 Earnings: Misses Expectations
GlobeNewswire
10 days ago
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
Simply Wall St.
18 days ago
Oculis Holding AG's (NASDAQ:OCS) largest shareholders are individual investors with 56% ownership, institutions own 39%
GlobeNewswire
a month ago
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
GlobeNewswire
a month ago
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
GlobeNewswire
a month ago
Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024
Compare OCS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCS Oculis Holding AG Ordinary shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.